For example, guanylyl cyclase C (GUCY2C)-targeted CAR-T cells can reduce CT26 colorectal cancer burden in the lungs of mice and extend survival when compared with CAR-T-cell control-treated mice.64,65 Human macrophages have also been engineered with CD3ζ-based CARs similar to T-cell CARs in order to direct the phagocytic activity of these cells against tumours, and these CAR-Ms reduce the burden of lung tumours by ovarian SKOV3 cancer cells.66 These HER2-directed CAR-Ms effectively reduced tumour burden and recruited T-cells and presented antigens to them. This evidence concerns the gene GUCY2C and neoplasm.